Literature DB >> 14966774

Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure.

Carlos H Del Carlo1, Antonio C Pereira-Barretto, Célia Cassaro-Strunz, Maria Do Rosário D O Latorre, José A Franchini Ramires.   

Abstract

BACKGROUND: This study determined whether serial determinations of cardiac troponin T (cTnT) in decompensated heart failure (HF) are predictive of clinical events (death, need for readmission for new episode of HF decompensation, or both) during 1 year of follow-up. METHODS AND
RESULTS: Sixty-two patients with decompensated HF were enrolled in this cohort. The first measurement of cTnT (cTnT1) was from a blood sample drawn within 4 days of hospital admission; the second measurement (cTnT2) was on blood obtained 7 days later. Forty-nine clinical events (16 deaths, 10 readmissions, 23 combined readmission and deaths) occurred during the follow-up. The independent predictors of clinical events were: cTnT1>.020 ng/mL (P<.050), cTnT2>.020 ng/mL (P<.050), and serum sodium<135 mEq/L (P<.050). Based on levels of cTnT1 and cTnT2>.020 ng/mL (+) or </=0.020 ng/mL(-), patients were divided into 2 groups: group 1 (cTnT1-, cTnT2- or cTnT1+, cTnT2-), group 2 (cTnT1-, cTnT2+ or cTnT1+, cTnT2+). Group 2 patients had higher rates of death (45.0% versus 71.4%, P<.050), hospital readmission (35.0% versus 61.9%, P<.050), and clinical events (55.0% versus 90.5%, P<.010) than group 1 patients.
CONCLUSIONS: Persistently increased cTnT levels (>.020 ng/mL) are predictive of higher rates of death and hospital readmission for decompensated HF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966774     DOI: 10.1016/s1071-9164(03)00594-3

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  13 in total

1.  Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study.

Authors:  Sunil K Agarwal; Christy L Avery; Christie M Ballantyne; Diane Catellier; Vijay Nambi; Justin Saunders; A Richey Sharrett; Josef Coresh; Gerardo Heiss; Ron C Hoogeveen
Journal:  Clin Chem       Date:  2011-04-25       Impact factor: 8.327

2.  Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation.

Authors:  Marco Metra; Luca Bettari; Franca Pagani; Valentina Lazzarini; Carlo Lombardi; Valentina Carubelli; Graziella Bonetti; Silvia Bugatti; Giovanni Parrinello; Luigi Caimi; G Michael Felker; Livio Dei Cas
Journal:  Clin Res Cardiol       Date:  2012-03-10       Impact factor: 5.460

Review 3.  An update on cardiac troponins as circulating biomarkers in heart failure.

Authors:  Serge Masson; Roberto Latini; Inder S Anand
Journal:  Curr Heart Fail Rep       Date:  2010-03

4.  Role of Cardiac Troponin Levels in Acute Heart Failure.

Authors:  Nicholas Wettersten; Alan Maisel
Journal:  Card Fail Rev       Date:  2015-10

5.  Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.

Authors:  J T Parissis; S Adamopoulos; D Farmakis; G Filippatos; I Paraskevaidis; F Panou; E Iliodromitis; D Th Kremastinos
Journal:  Heart       Date:  2006-12       Impact factor: 5.994

6.  Elevated troponin T on discharge predicts poor outcome of decompensated heart failure.

Authors:  Kimi Koide; Tsutomu Yoshikawa; Yuji Nagatomo; Shun Kohsaka; Toshihisa Anzai; Tomomi Meguro; Satoshi Ogawa
Journal:  Heart Vessels       Date:  2010-05-29       Impact factor: 2.037

Review 7.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

Review 8.  Determinants of survival following hospitalization for acute heart failure.

Authors:  Marwan F Jumean; Michael S Kiernan
Journal:  Curr Heart Fail Rep       Date:  2014-06

9.  Temporal variation in the prognosis and treatment of advanced heart failure - before and after 2000.

Authors:  Carlos Henrique Del Carlo; Juliano Novaes Cardoso; Marcelo Eidi Ochia; Mucio Tavares de Oliveira; José Antonio Franchini Ramires; Antonio Carlos Pereira-Barretto
Journal:  Arq Bras Cardiol       Date:  2014-04-17       Impact factor: 2.000

10.  Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage.

Authors:  Chikao Ibuki; Yoshihiko Seino; Toshiaki Otsuka; Nakahisa Kimata; Toru Inami; Ryo Munakata; Kyoichi Mizuno
Journal:  J Clin Med Res       Date:  2012-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.